Loading WST detail
Loading ticker data...
Loading WST detail
West Pharmaceutical Services, Inc. designs, manufactures, and sells containment and delivery systems for injectable drugs and healthcare products in the Americas, Europe, the Middle East, Africa, and the Asia Pacific.
It operates in two segments, Proprietary Products and Contract-Manufactured Products. The Proprietary Products segment offers stoppers and seals for injectable packaging systems; syringe and cartridge components, including custom solutions for the needs of injectable drug applications, as well as administration systems that enhance the safe delivery of drugs through advanced reconstitution, mixing, and transfer technologies; and films, coatings, washing, and vision inspection and sterilization processes and services to enhance the quality of packaging components. It also provides drug containment solutions, including Crystal Zenith, a cyclic olefin polymer in the form of vials, syringes, and cartridges; and self-injection devices, as well as a range of integrated solutions, including analytical lab services, pre-approval primary packaging support and engineering development, regulatory expertise, and after-sales technical support. This segment serves biologic, generic, and pharmaceutical drug companies. The Contract-Manufactured Products segment is involved in the design, manufacture, and automated assembly of devices used in surgical, diagnostic, ophthalmic, injectable, and other drug delivery systems, as well as consumer products. It serves pharmaceutical, diagnostic, and medical device companies. The company distributes its products through its sales force and distribution network, as well as contract sales agents and regional distributors.
West Pharmaceutical Services, Inc. was incorporated in 1923 and is headquartered in Exton, Pennsylvania.
Chart data unavailable
EXTON, Pa., April 9, 2026 /PRNewswire/ -- West Pharmaceutical Services, Inc. (NYSE: WST), a global leader in innovative solutions for injectable drug administration, today announced that it will release first-quarter 2026 financial results before the market opens on Thursday, April 23, 2026, and will follow with a conference call to discuss the results and business expectations at 8:00 a.m. Eastern Time.
Investors looking for stocks in the Medical - Dental Supplies sector might want to consider either Align Technology (ALGN) or West Pharmaceutical Services (WST). But which of these two stocks is more attractive to value investors?
West Pharmaceutical expands Dublin facility to boost injectable therapy capacity and strengthen its end-to-end manufacturing platform.
I am shifting capital allocation toward scarcity-driven assets like energy, metals, infrastructure, and defense, as the abundance trade in software faces structural disruption from AI. My TOLL framework prioritizes companies with hard assets, durable competitive moats, and long-duration cash flows that are less vulnerable to AI-driven commoditization. Key investment themes include nuclear utilities (VST, CEG), copper producers (FCX), gold/silver streamers (FNV, WPM), grid/infrastructure suppliers (ETN, FIX), and defense/aerospace leaders (RTX, TDG).
EXTON, Pa., March 31, 2026 /PRNewswire/ -- West Pharmaceutical Services, Inc. (NYSE: WST), a global leader in innovative solutions for injectable drug administration, announced today the opening of its new building at its current site in Damastown, Dublin. The 165,000 square foot expansion significantly enhances West's contract services and is designed to meet growing global demands of its customers' high-volume treatments, including diabetes and obesity.
Wealth Enhancement Advisory Services LLC trimmed its stake in shares of West Pharmaceutical Services, Inc. (NYSE: WST) by 26.4% in the undefined quarter, according to its most recent disclosure with the SEC. The institutional investor owned 21,480 shares of the medical instruments supplier's stock after selling 7,693 shares during the period. Wealth Enhancement
Investors interested in stocks from the Medical - Dental Supplies sector have probably already heard of Align Technology (ALGN) and West Pharmaceutical Services (WST). But which of these two companies is the best option for those looking for undervalued stocks?
West Pharmaceutical Services, Inc. (WST) Presents at 2026 KeyBanc Capital Markets Healthcare Virtual Forum Transcript
Cinctive Capital Management LP bought a new stake in shares of West Pharmaceutical Services, Inc. (NYSE: WST) in the undefined quarter, according to the company in its most recent filing with the Securities and Exchange Commission. The fund bought 14,319 shares of the medical instruments supplier's stock, valued at approximately $3,756,000. Other institutional
Brown Brothers Harriman and Co. lifted its holdings in West Pharmaceutical Services, Inc. (NYSE: WST) by 22.2% during the third quarter, according to the company in its most recent Form 13F filing with the Securities and Exchange Commission. The institutional investor owned 247,356 shares of the medical instruments supplier's stock after purchasing an
Middle East tensions rattle markets as oil tops $100. Atmos Energy, Colgate-Palmolive and West Pharmaceutical Services stand out as dividend aristocrats for stability.
WST eyes growth from high-value components, GLP-1 drug demand and Annex 1 conversions, but generics destocking and European capacity constraints pose risks.
West Pharmaceutical Services, Inc. (WST) Presents at Barclays 28th Annual Global Healthcare Conference Transcript
West Pharmaceutical's chief executive Eric Green said on Monaday he plans to retire once the company finds his successor, ending an 11-year run at the helm.
EXTON, Pa., March 9, 2026 /PRNewswire/ -- West Pharmaceutical Services, Inc. (NYSE: WST) announced today that Eric M. Green has informed the Board of Directors that he plans to retire from his positions as President, Chief Executive Officer and Chair of the Board of the Company once his successor has been hired in order to ensure a smooth transition.
